MX2022015407A - Metodos de tratamiento del complejo de esclerosis tuberosa. - Google Patents

Metodos de tratamiento del complejo de esclerosis tuberosa.

Info

Publication number
MX2022015407A
MX2022015407A MX2022015407A MX2022015407A MX2022015407A MX 2022015407 A MX2022015407 A MX 2022015407A MX 2022015407 A MX2022015407 A MX 2022015407A MX 2022015407 A MX2022015407 A MX 2022015407A MX 2022015407 A MX2022015407 A MX 2022015407A
Authority
MX
Mexico
Prior art keywords
methods
tuberous sclerosis
treatment
sclerosis complex
subject
Prior art date
Application number
MX2022015407A
Other languages
English (en)
Spanish (es)
Inventor
George Garibaldi
Original Assignee
Noema Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noema Pharma Ag filed Critical Noema Pharma Ag
Publication of MX2022015407A publication Critical patent/MX2022015407A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Preparation Of Fruits And Vegetables (AREA)
  • Medicinal Preparation (AREA)
MX2022015407A 2020-06-05 2021-06-04 Metodos de tratamiento del complejo de esclerosis tuberosa. MX2022015407A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063035313P 2020-06-05 2020-06-05
PCT/EP2021/065075 WO2021245281A1 (en) 2020-06-05 2021-06-04 Methods of treatment of tuberous sclerosis complex

Publications (1)

Publication Number Publication Date
MX2022015407A true MX2022015407A (es) 2023-05-16

Family

ID=76325558

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015407A MX2022015407A (es) 2020-06-05 2021-06-04 Metodos de tratamiento del complejo de esclerosis tuberosa.

Country Status (13)

Country Link
US (3) US11684613B2 (enExample)
EP (1) EP4161512A1 (enExample)
JP (2) JP2023528895A (enExample)
KR (2) KR20230027145A (enExample)
CN (1) CN116056701A (enExample)
AU (1) AU2021285273A1 (enExample)
BR (1) BR112022024760A2 (enExample)
CA (1) CA3180794A1 (enExample)
CL (1) CL2022003435A1 (enExample)
IL (2) IL322310A (enExample)
MX (1) MX2022015407A (enExample)
PH (1) PH12023550016A1 (enExample)
WO (1) WO2021245281A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022015407A (es) * 2020-06-05 2023-05-16 Noema Pharma Ag Metodos de tratamiento del complejo de esclerosis tuberosa.
CN120641098A (zh) * 2023-02-02 2025-09-12 诺埃玛制药公司 Dravet综合征的治疗方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508560A (en) 1981-11-11 1985-04-02 Ciba Geigy Corporation Certain pyridylacetylene compounds, compositions containing same and herbicidal methods of use
CN100548299C (zh) 2001-01-05 2009-10-14 伊莱利利公司 兴奋性氨基酸受体拮抗剂
TWI292318B (en) 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
HRP20080363T3 (hr) 2004-06-01 2008-09-30 F. Hoffmann - La Roche Ag Piridin-4-il-etinil-imidazoli i pirazoli kao antagonisti mglu5 receptora
EP1756086B1 (en) 2004-06-01 2008-06-04 F.Hoffmann-La Roche Ag Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists
AU2007336369B2 (en) * 2006-12-21 2013-01-17 F. Hoffmann-La Roche Ag Polymorphs of a mGluR5 receptor antagonist
US8211882B2 (en) 2008-03-08 2012-07-03 Richard Delarey Wood Glutamate receptor modulators and therapeutic agents
JP2013505262A (ja) 2009-09-17 2013-02-14 バンダービルト ユニバーシティー mGluR5ネガティブアロステリックモジュレータとしての置換ヘテロアリールアミンカルボキサミド類似体、ならびに、その形成方法および使用方法
US20120039999A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
CA2845578C (en) 2011-08-25 2016-02-16 Merck Sharp & Dohme Corp. Pyrimidine pde10 inhibitors
MX2022015407A (es) * 2020-06-05 2023-05-16 Noema Pharma Ag Metodos de tratamiento del complejo de esclerosis tuberosa.
TWI924682B (zh) 2020-07-30 2026-05-11 瑞士商諾埃瑪製藥公司 三叉神經痛之治療方法
US20240285637A1 (en) 2021-07-08 2024-08-29 The Royal Institution For The Advancement Of Learning/Mcgill University Phosphodiesterase inhibitors for the mitigation of fragile x syndrome symptoms
CN119677515A (zh) 2022-06-15 2025-03-21 美国政府健康及人类服务部 使用代谢型谷氨酸受体5拮抗剂或/和大麻素受体1拮抗剂治疗纤维化疾病
EP4584250A4 (en) 2022-09-06 2026-02-25 Biohaven Therapeutics Ltd POLYTHERAPIES INCLUDING METAL CHANNEL ACTIVATORS
US20260124188A1 (en) 2022-10-28 2026-05-07 Orphelion Ab mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal
CN120641098A (zh) 2023-02-02 2025-09-12 诺埃玛制药公司 Dravet综合征的治疗方法
EP4680203A1 (en) 2023-03-14 2026-01-21 Prolevi Bio AB Compositions for sustained release of poorly soluble active ingredients

Also Published As

Publication number Publication date
IL322310A (en) 2025-09-01
CL2022003435A1 (es) 2023-10-20
US12702661B2 (en) 2026-08-11
PH12023550016A1 (en) 2024-03-11
KR20250116184A (ko) 2025-07-31
US20230100520A1 (en) 2023-03-30
US11998535B2 (en) 2024-06-04
IL298709A (en) 2023-02-01
JP2023528895A (ja) 2023-07-06
JP2025122066A (ja) 2025-08-20
BR112022024760A2 (pt) 2023-03-07
WO2021245281A1 (en) 2021-12-09
US20230277513A1 (en) 2023-09-07
EP4161512A1 (en) 2023-04-12
CN116056701A (zh) 2023-05-02
CA3180794A1 (en) 2021-12-09
AU2021285273A1 (en) 2023-01-19
KR20230027145A (ko) 2023-02-27
US20250099445A1 (en) 2025-03-27
US11684613B2 (en) 2023-06-27

Similar Documents

Publication Publication Date Title
PH12019501222A1 (en) Cyclic dinucleotides as sting (stimulator of interferon genes) agonists
MX2020010407A (es) Benzotiofenos y compuestos relacionados como agonistas de sting.
PH12018502534A1 (en) Heteroaryl substituted pyridines and methods of use
MX389965B (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos
EP4635568A3 (en) Compounds, salts thereof and methods for treatment of diseases
MX2019011530A (es) Saxitoxinas 11,13-modificadas para el tratamiento del dolor.
PH12020550585A1 (en) Sting modulator compounds, and methods of making and using
MY209310A (en) Sting agonistic compound
MX392829B (es) Analogos sinteticos de las ecteinascidinas y su uso como agentes antitumorales
MX2021010700A (es) Compuestos utiles en la terapia del vih.
EP4306541A3 (en) Anti-ifnar1 dosing regime for subcutaneous injection
CR20230413A (es) Moduladores de sting (estimulador de genes de interferón)
PH12023550016A1 (en) Methods of treatment of tuberous sclerosis complex
MX2020011817A (es) Metodos para tratar el linfoma.
MX2015011280A (es) Moduladores de ship1 y metodos relacionados con los mismos.
BR112022003659A2 (pt) Composições e métodos de tratamento de doenças vasculares
EA201991988A1 (ru) Композиции и способы для способствования росту волос с помощью ингибиторов mpc1
PH12020551117A1 (en) Compositions for preventing or treating uveitis
MX2025008911A (es) Metodos de tratamiento del sindrome de dravet
EA201891808A1 (ru) Трис-амидные соединения и композиции, содержащие их
MX2024010480A (es) Uso de inhibidor de captacion triple para el tratamiento de la depresion atipica.
PH12023550204A1 (en) Methods of treatment of trigeminal neuralgia
RU2014123690A (ru) Терапевтическое средство при артрозе
MX2023003035A (es) Compuestos como moduladores de bis-fosfoglicerato mutasa para el tratamiento de la anemia de celulas falciforme.
MX2022014889A (es) Polioles de alquílo mononitrosilados y bisnitrosilados para su uso terapéutico.